Phase 1 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to give written consent and are able to attend scheduled visits and follow the trial procedures
• Men or women between the ages of 18 and 75
• People who have been confirmed through tissue or cell testing to have advanced colorectal cancer
• People whose cancer has continued to grow despite standard treatment, who are not suitable for standard treatment, for whom no standard treatment exists, or who have chosen not to receive standard treatment
• People whose major organs (such as liver, kidneys, and bone marrow) are functioning adequately
• People who have at least one measurable tumour that can be tracked on scans, according to standard measurement guidelines
• People who are reasonably active and able to carry out daily activities, with a performance score of 0 or 1 on a standard scale used by doctors (confirm with trial site)
• People with a life expectancy of at least 3 months
• People of childbearing potential (both women and men whose partners could become pregnant) who agree to use reliable contraception throughout treatment and for 6 months after treatment ends

Who may not be able to join:

• Women who are pregnant, breastfeeding, or planning to become pregnant during the trial or within 6 months after the last dose
• People with active epileptic seizures or active spread of cancer to the brain or central nervous system
• People with significant heart or stroke-related conditions
• People with certain serious lung conditions, such as interstitial lung disease, pulmonary fibrosis, or radiation-related lung damage, especially if treatment is required, or those with a history of severely reduced lung function
• People with a history of allergies, asthma, or atopic dermatitis (a type of chronic skin condition)
• People with large amounts of fluid build-up around the lungs or in the abdomen
• People with an active autoimmune disease that has required medical treatment in the 2 years before joining the trial
• People who have previously had an organ transplant or a bone marrow/stem cell transplant from a donor
• People with a known or suspected allergy to the study drug or any of its ingredients
• People who previously had to permanently stop taking an immune checkpoint inhibitor or the drug Bevacizumab due to serious side effects
• People who still have unresolved side effects rated above a mild level (Grade 1) from previous cancer treatments, with some exceptions such as ongoing hair loss or mild nerve-related symptoms
• People with active uncontrolled bleeding or a known tendency to bleed
• People who have had major surgery within 4 weeks before starting the trial
• People who have tested positive for HIV, or have active hepatitis B, hepatitis C, or tuberculosis
• People with a severe, active, or uncontrolled infection, or who have had an unexplained fever requiring intravenous antibiotics within the 2 weeks before starting the trial
• People who have been diagnosed with another type of cancer within the past 5 years (some exceptions may apply, such as certain treated skin cancers, localised prostate cancer, or papillary thyroid cancer — confirm with trial site)
• People with any other condition, treatment history, test result, or substance use history that, in the doctor's judgement, could affect safety, consent, or the reliability of the trial results

Important: Always verify eligibility with the trial site directly before applying.